Vibliome Therapeutics, LLC, has developed a novel systematic approach that enables the design of small molecule kinase inhibitors with unique selectivity profiles and extraordinary selectivity. There are over 500 kinases in the human genome which control nearly all cellular functions by transferring a polar phosphate group from ATP to regulatory serine, threonine, or tyrosine residues on proteins. Our mission to develop new therapeutic options for patients is backed by Deerfield Management in New York, a private equity firm committed to improving healthcare through investment, information and philanthropy. Consistent with our pioneering spirit, Vibliome’s research operations are located in Bozeman, Montana, on the edge of Yellowstone National Park and in the midst of world class skiing, fly fishing, unsurpassed access to nature and Montana’s largest research university. We are always looking for creative professionals with broad experience in drug discovery and development to join our team as we continue to grow.